Sanofi shaves 207 R&D jobs in scaled-back reorg

Under assault from union leaders and government officials, Sanofi ($SNY) was forced to back off plans to engineer a major reorganization of its R&D operations in France. But it's going ahead with a scaled-back effort aimed at concentrating its forces in key corporate hubs while trimming the overall number of researchers on the payroll. Report

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.